药物基本信息
通用名：纳豆激酶
适应症：适用于心脑血管障碍及高血脂，高粘血症，高血压，动脉硬化，冠心病，脑血栓，心脑供血不足，中风后遗症等人群服用。
市场需求
纳豆激酶（NK）治疗与预防血栓性疾病药物的市场需求非常大。目前，我国抗血栓药物市场的年销售额保持着近两成的年增长率。临床使用的尿激酶、链激酶等抗血栓药物在临床使用过程中存在稳定性差、药物作用时间短、半衰期短、来源少、成本昂贵、易引起患者出血等副作用。与其他溶栓药物相比，NK具有纤溶活性强、安全性能好、成本低廉、可口服、维持时间长等优点。因此NK本身所具有的良好的生理调节功能和溶栓活性使其成为了一种治疗和预防血栓和栓塞性疾病的理想药物，具有良好的开发前景。
The basic information of drug
Common name: Nattokinase
Indications: treatment of Cardiovascular and cerebrovascular disorders and hyperlipidemia, hyperviscosity, hypertension, atherosclerosis, coronary heart disease, cerebral thrombosis, heart and brain insufficiency, stroke sequelae and so on.
Market demand
The market demand natto kinase (NK) treatment and prevention of thrombotic disease drugs is very large. At present, In China, the annual sales of antithrombotic drug market maintain nearly 20% annual growth rate. Clinical use of urokinase, streptokinase and other anti-thrombotic drugs in the process of clinical use is poor stability, short drug action time, short half-life, less source, expensive, easy to cause bleeding and other side effects. Compared with other thrombolytic drugs, NK has the advantages of strong fibrinolytic activity, good safety performance, low cost, oral administration and long maintenance time. Therefore, NK itself has a good physiological regulation function and thrombolytic activity to become a treatment and prevention of thrombosis and embolism of the ideal drug, has a good development prospects.
